20 participants
SIRT With Tremelimumab and Durvalumab for Resectable HCC
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-08-13
- Start Date:
- 2023-04-21
- Completion:
- 2026-10-01
Conditions
- Resectable Hepatocellular Carcinoma
- Hepatocellular Carcinoma
- Hepatocellular Cancer
Interventions
- DRUG
- DEVICE
No Results Yet